Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

Dimopoulos, Meletios A.; Goldschmidt, Hartmut; Niesvizky, Ruben; Joshua, Douglas; Chng, Wee-Joo; Oriol, Albert; Orlowski, Robert Z.; Ludwig, Heinz; Facon, Thierry; Hajek, Roman; Weisel, Katja; Hungria, Vania; Minuk, Leonard; Feng, Shibao; Zahlten-Kumeli, Anita; Kimball, Amy S.; Moreau, Philippe

dc.contributor.author	Weisel, Katja
dc.date.accessioned	2019-04-23T13:03:48Z
dc.date.available	2019-04-23T13:03:48Z
dc.date.issued	2017
dc.identifier.issn	1474-5488
dc.identifier.uri	http://hdl.handle.net/10900/88013
dc.language.iso	en	de_DE
dc.publisher	Elsevier Science Inc	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/S1470-2045(17)30578-8	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190131163842_00973
utue.publikation.seiten	1327-1337	de_DE
utue.personen.roh	Dimopoulos, Meletios A.
utue.personen.roh	Goldschmidt, Hartmut
utue.personen.roh	Niesvizky, Ruben
utue.personen.roh	Joshua, Douglas
utue.personen.roh	Chng, Wee-Joo
utue.personen.roh	Oriol, Albert
utue.personen.roh	Orlowski, Robert Z.
utue.personen.roh	Ludwig, Heinz
utue.personen.roh	Facon, Thierry
utue.personen.roh	Hajek, Roman
utue.personen.roh	Weisel, Katja
utue.personen.roh	Hungria, Vania
utue.personen.roh	Minuk, Leonard
utue.personen.roh	Feng, Shibao
utue.personen.roh	Zahlten-Kumeli, Anita
utue.personen.roh	Kimball, Amy S.
utue.personen.roh	Moreau, Philippe
dcterms.isPartOf.ZSTitelID	Lancet Oncology	de_DE
dcterms.isPartOf.ZS-Issue	10	de_DE
dcterms.isPartOf.ZS-Volume	18	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE